Header Logo

Connection

JIUN-KAE JACK LEE to Head and Neck Neoplasms

Back to Details
This is a "connection" page, showing publications JIUN-KAE JACK LEE has written about Head and Neck Neoplasms.
JIUN-KAE JACK LEE
Connection Strength
1.044
Head and Neck Neoplasms
  1. Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res (Phila). 2011 Feb; 4(2):185-93.
    View in: PubMed
    Score: 0.126
  2. Differential expression profiling of head and neck squamous carcinoma: significance in their phenotypic and biological classification. Oncogene. 2002 Nov 21; 21(53):8206-19.
    View in: PubMed
    Score: 0.071
  3. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2015 Jul; 26(7):1476-80.
    View in: PubMed
    Score: 0.042
  4. Epidemiology of head and neck squamous cell cancer among HIV-infected patients. J Acquir Immune Defic Syndr. 2014 Apr 15; 65(5):603-10.
    View in: PubMed
    Score: 0.039
  5. Short telomere lengths in peripheral blood leukocytes are associated with an increased risk of oral premalignant lesion and oral squamous cell carcinoma. Cancer. 2013 Dec 15; 119(24):4277-83.
    View in: PubMed
    Score: 0.038
  6. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention. Clin Cancer Res. 2012 Jul 01; 18(13):3705-13.
    View in: PubMed
    Score: 0.034
  7. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol. 2011 Dec; 6(12):2104-11.
    View in: PubMed
    Score: 0.033
  8. Canadian Optically-guided approach for Oral Lesions Surgical (COOLS) trial: study protocol for a randomized controlled trial. BMC Cancer. 2011 Oct 25; 11:462.
    View in: PubMed
    Score: 0.033
  9. KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma. Oncogene. 2011 Jul 14; 30(28):3163-73.
    View in: PubMed
    Score: 0.032
  10. DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. Clin Cancer Res. 2011 Apr 01; 17(7):2035-43.
    View in: PubMed
    Score: 0.032
  11. MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer. Carcinogenesis. 2010 Dec; 31(12):2118-23.
    View in: PubMed
    Score: 0.031
  12. Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma. Carcinogenesis. 2010 Oct; 31(10):1755-61.
    View in: PubMed
    Score: 0.030
  13. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther. 2010 Jun; 9(6):1755-63.
    View in: PubMed
    Score: 0.030
  14. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol. 2010 Jan 01; 28(1):8-14.
    View in: PubMed
    Score: 0.029
  15. Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res (Phila). 2009 Jul; 2(7):617-24.
    View in: PubMed
    Score: 0.028
  16. Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol. 2009 May 20; 27(15):2509-15.
    View in: PubMed
    Score: 0.028
  17. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol. 2007 Jun 01; 25(16):2164-70.
    View in: PubMed
    Score: 0.024
  18. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2006 Sep 01; 24(25):4163-9.
    View in: PubMed
    Score: 0.023
  19. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst. 2006 Apr 05; 98(7):441-50.
    View in: PubMed
    Score: 0.022
  20. Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. Laryngoscope. 2005 Sep; 115(9):1561-7.
    View in: PubMed
    Score: 0.022
  21. Loss of E-cadherin and p27 expression is associated with head and neck squamous tumorigenesis. Cancer. 2005 Mar 01; 103(5):952-9.
    View in: PubMed
    Score: 0.021
  22. Loss of Fhit expression in head and neck squamous cell carcinoma and its potential clinical implication. Clin Cancer Res. 2004 Aug 15; 10(16):5554-7.
    View in: PubMed
    Score: 0.020
  23. Tetranucleotide microsatellite instability in surgical margins for prediction of local recurrence of head and neck squamous cell carcinoma. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4022-8.
    View in: PubMed
    Score: 0.020
  24. Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis. Clin Cancer Res. 2004 Mar 01; 10(5):1733-42.
    View in: PubMed
    Score: 0.019
  25. Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States). Cancer Causes Control. 2003 Mar; 14(2):131-8.
    View in: PubMed
    Score: 0.018
  26. Biologic correlates of a biochemoprevention trial in advanced upper aerodigestive tract premalignant lesions. Cancer Epidemiol Biomarkers Prev. 2002 Dec; 11(12):1605-10.
    View in: PubMed
    Score: 0.018
  27. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev. 2001 Aug; 10(8):823-9.
    View in: PubMed
    Score: 0.016
  28. p53 protein accumulation and genomic instability in head and neck multistep tumorigenesis. Cancer Epidemiol Biomarkers Prev. 2001 Jun; 10(6):603-9.
    View in: PubMed
    Score: 0.016
  29. Expression of vascular endothelial growth factor and microvessel density in head and neck tumorigenesis. Clin Cancer Res. 2000 Jul; 6(7):2821-8.
    View in: PubMed
    Score: 0.015
  30. Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression. J Natl Cancer Inst. 2000 Jan 05; 92(1):69-73.
    View in: PubMed
    Score: 0.015
  31. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst. 1998 Oct 21; 90(20):1545-51.
    View in: PubMed
    Score: 0.013
  32. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol. 1998 Apr; 16(4):1325-30.
    View in: PubMed
    Score: 0.013
  33. Mutagen sensitivity as a predictor of tumor recurrence in patients with cancer of the upper aerodigestive tract. J Natl Cancer Inst. 1998 Feb 04; 90(3):243-5.
    View in: PubMed
    Score: 0.013
  34. Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. Am J Pathol. 1997 Dec; 151(6):1767-74.
    View in: PubMed
    Score: 0.013
  35. Correlates of mutagen sensitivity in patients with upper aerodigestive tract cancer. Cancer Epidemiol Biomarkers Prev. 1997 Sep; 6(9):687-92.
    View in: PubMed
    Score: 0.012
  36. Comparison of p53 immunoreactivity in fresh-cut versus stored slides with and without microwave heating. Mod Pathol. 1997 Mar; 10(3):224-30.
    View in: PubMed
    Score: 0.012
  37. Cisplatin, fluorouracil, and L-leucovorin induction chemotherapy for locally advanced head and neck cancer: the M.D. Anderson Cancer Center experience. Cancer J Sci Am. 1997 Mar-Apr; 3(2):92-9.
    View in: PubMed
    Score: 0.012
  38. p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst. 1996 Apr 17; 88(8):519-29.
    View in: PubMed
    Score: 0.011
  39. In vitro protective effects of chemopreventive agents against bleomycin-induced genotoxicity in lymphoblastoid cell lines and peripheral blood lymphocytes of head and neck cancer patients. Cancer Detect Prev. 1993; 17(6):575-83.
    View in: PubMed
    Score: 0.009
  40. Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies. Cancer. 2004 Dec 15; 101(12):2837-42.
    View in: PubMed
    Score: 0.005
  41. Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis: long-term follow-up. J Natl Cancer Inst. 1997 Feb 05; 89(3):257-8.
    View in: PubMed
    Score: 0.003
  42. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med. 1993 Jan 07; 328(1):15-20.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.